3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Motor Activity
9
Breast Neoplasms
6
Neoplasms
4
Colorectal Neoplasms
3
Multiple Myeloma
2
Insulin Resistance
2
Cardiotoxicity
2
Weight Loss
1
Warts
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Peripheral Nervous System Diseases
1
Ovarian Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Lymphoma
1
Limb-girdle muscular dystrophy, type 2C
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Fatigue
1
Diabetes Mellitus, Type 2
1
Diabetes Mellitus
1
Cognitive Dysfunction
1
Carcinoma, Hepatocellular
1
Cachexia
1
Brenner Tumor
1
Bone Metastases
1
Body Weight
1
Interventions
Trastuzumab
3
Sugammadex
2
Neostigmine
2
Cisplatin
2
valrubicin
1
tucatinib
1
pembrolizumab
1
niraparib
1
enfortumab vedotin
1
avelumab
1
atezolizumab
1
Surveys and Questionnaires
1
Sunitinib
1
Standard of Care
1
Rocuronium
1
Pemetrexed
1
Paclitaxel
1
Nephroureterectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Lymph Node Excision
1
Glycopyrrolate
1
Gemcitabine
1
GSK-3326595
1
Fulvestrant
1
Docetaxel
1
Cetuximab
1
Afatinib
1
Administration, Intravesical
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urologic Neoplasms
×
Exercise
×
Clear all
No trials found.